Tag Archives: photosensitizer

Modulight Spotlights: LASER-SHARP RESEARCH – September 2024

 Modulight Spotlights: LASER-SHARP RESEARCH – September 2024 University of Maryland and Modulight have published together a new research study about the mechanisms of cancer drug resistance. Drug resistance is a leading cause of treatment failure and often has dramatic consequences for survival of cancer patients. Cancer cells have developed various ways to protect themselves from drugs. When several clinically used photoactive drugs were studied, it was shown that some of them were being actively pumped out by cancer cells, thus likely limiting the full therapeutic potential Continue reading →

Ru(II) Oligothienyl Complexes with Fluorinated Ligands: Photophysical, Electrochemical, and Photobiological Properties

Published in: Inorganic Chemistry Authors: Houston D. Cole, Abbas Vali, John A. Roque III, Ge Shi, Alisher Talgatov, Gurleen Kaur, Antonio Francés-Monerris, Marta E. Alberto, Colin G. Cameron, Sherri A. McFarland  Published in: Inorganic Chemistry Authors: Houston D. Cole, Abbas Vali, John A. Roque III, Ge Shi, Alisher Talgatov, Gurleen Kaur, Antonio Francés-Monerris, Marta E. Alberto, Colin G. Cameron, Sherri A. McFarland A series of Ru(II) complexes were characterized and assessed for phototherapy effects toward cancer cells. Also activity in hypoxia was evaluated, with some of the compounds retaining partial activity in hypoxia. ML8500 was used for dosimetry studies, assessing impact of irradiance on the phototoxicity of Ru-4T with several different wavelengths. LEDs were used for Continue reading →

Photoimmuno-antimicrobial therapy for Staphylococcus aureus implant infection

Published in: PLoS One Authors: Bruce van Dijk, Sabrina Oliveira, J. Fred F. Hooning van Duyvenbode, F. Ruben H. A. Nurmohamed, Vida Mashayekhi, Irati Beltrán Hernández, Jos van Strijp, Lisanne de Vor, Piet C. Aerts, H. Charles Vogely, Harrie Weinans, Bart C. H. van der Wal  Published in: PLoS One Authors: Bruce van Dijk, Sabrina Oliveira, J. Fred F. Hooning van Duyvenbode, F. Ruben H. A. Nurmohamed, Vida Mashayekhi, Irati Beltrán Hernández, Jos van Strijp, Lisanne de Vor, Piet C. Aerts, H. Charles Vogely, Harrie Weinans, Bart C. H. van der Wal Photoimmuno-antimicrobial therapy (PIAT) was develop to treat implant infections that cause high morbidity and mortality worldwide. Antibody targeting Wall Teichoic Acid surface components of both S. aureus and its biofilm was conjugated to a photosensitizer IRDye700DX and used as Continue reading →

Carrier-Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery

Published in: Advanced Science Authors: John A. Quinlan, Collin T. Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly, Robert W. Robey, Graeme F. Woodworth, Michael M. Gottesman, Huang-Chiao Huang University of Maryland  Published in: Advanced Science Authors: John A. Quinlan, Collin T. Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly, Robert W. Robey, Graeme F. Woodworth, Michael M. Gottesman, Huang-Chiao Huang University of Maryland Glioblastoma (GBM) is hard to treat due to cellular invasion into functioning brain tissues, limited drug delivery, and evolved treatment resistance. Recurrence is nearly universal even after surgery, chemotherapy, and radiation. Photodynamic therapy (PDT) involves photosensitizer administration followed by light activation to generate reactive oxygen species at tumor sites, thereby killing cells or Continue reading →

Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids

Published in: Cell & Bioscience Authors: Aaron Sorrin, Anika Dasgupta, Kathryn McNaughton, Carla Arnau Del Valle, Keri Zhou, Cindy Liu, Dana M. Roque & Huang Chiao Huang Within the last decade, poly(ADP-ribose) polymerase inhibitors (PARPi) have emerged in the clinic as an effective treatment for numerous malignancies. Preclinical data have demonstrated powerful combination effects of PARPi paired with photodynamic therapy (PDT), which involves light-activation of specialized dyes (photosensitizers) to stimulate cancer cell death through reactive oxygen species generation. In this study, a novel combination strategy was Continue reading →

Transient fluid flow improves photoimmunoconjugate delivery and photoimmunotherapy efficacy

Published in: iScience Authors: Aaron J. Sorrin, Keri Zhou, Katherine May, Cindy Liu, Kathryn McNaughton, Idrisa Rahman, Barry J. Liang, Imran Rizvi, Dana M. Roque, Huang-Chiao Huang    Published in: iScience Authors: Aaron J. Sorrin, Keri Zhou, Katherine May, Cindy Liu, Kathryn McNaughton, Idrisa Rahman, Barry J. Liang, Imran Rizvi, Dana M. Roque, Huang-Chiao Huang   The study showed that fluid flow induced shear stress increased the photocytotoxicity of different photosensitizers tested (BPD, PIC, PIC-coated liposome) against ovarian cancer cells. The cellular delivery of photosensitizers doubled compared to static conditions. Modulight laser was used for PDT activation together with photosensitizer(s). Circulating drugs in the peritoneal cavity is an effective strategy for advanced ovarian Continue reading →

Pharmaceutical nanotechnology applied to phthalocyanines for the promotion of antimicrobial photodynamic therapy: A literature review

Published in: Photodiagnosis and Photodynamic Therapy Authors: Luciana Betzler de Oliveira de Siqueira, Ana Paula dos Santos Matos, Marcio Robert Mattos da Silva, Suvene Rocha Pinto, Ralph Santos-Oliveira, Eduardo Ricci-Júnior  Published in: Photodiagnosis and Photodynamic Therapy Authors: Luciana Betzler de Oliveira de Siqueira, Ana Paula dos Santos Matos, Marcio Robert Mattos da Silva, Suvene Rocha Pinto, Ralph Santos-Oliveira, Eduardo Ricci-Júnior   Phthalocyanines are photosensitizers activated by light at a specific wavelength in the presence of oxygen and act through the production of Reactive Oxygen Species, which simultaneously attack several biomolecular targets in the pathogen agent and, therefore, have multiple and variable action sites. This nonspecific action site bypasses conventional resistance mechanisms. Antimicrobial Photodynamic Therapy (aPDT) is Continue reading →

In vitro illumination using ML8500: osmium-based anticancer photosensitizer with highest hypoxic activity reported to date

  Sherri McFarland discussing how ML8500 is supporting her research   Study protocol to determine wavelength, fluence, and irradiance activities of Os-4T:   Key observations Illumination parameters significantly affected the phototoxicity of Os-4T. The green light (525 nm) was more effective than the red light (630 nm) at lower fluences, while the maximal potency was achieved at both wavelengths when using fluences higher than 100 J/cm2. Irradiance affected the potency with both the red and the green light that were more effective when lower irradiances Continue reading →Customer case Research by: University of Texas at Arlington, US. One of the leading groups in photoactive drug discovery. Developed first clinical-level rubidium-based PS (TLD-1433), now in Theralase-sponsored Phase 2 trials for bladder cancer. Modulight products: ML8500 (445 nm, 525 nm, 630 nm, 753 nm, 810 nm) Laser use: Photoactive drug discovery Link to the study: Prof. Sherri McFarland Research topics: Medicinal inorganic chemistry and drug discovery. Special interest in the synthesis of novel transition metal complexes and studying their interactions with light for the purpose Continue reading →

Towards high-throughput light-activated drug discovery using automated plate illuminator

Published in: SPIE BIOS 2021 Authors: Robert Perttilä, John Roque III, Lasse Orsila, Zoe Ylöniemi, Elias Kokko, Colin G. Cameron, Sherri A. McFarland, Petteri Uusimaa  Published in: SPIE BIOS 2021 Authors: Robert Perttilä, John Roque III, Lasse Orsila, Zoe Ylöniemi, Elias Kokko, Colin G. Cameron, Sherri A. McFarland, Petteri Uusimaa There is an ongoing need in photodynamic therapy (PDT) research to develop highly active photosensitizers (PSs) with improved characteristics combined with optimized treatment protocols to produce effective treatment with minimal side effects. While several novel PSs have undergone clinical trials or been approved in recent years, there remain few available instrumentation options for high-throughput screens (HTS) with in vitro PDT. The Modulight ML8500 was developed to address this Continue reading →

Configurable cloud based medical laser platform with real-time treatment monitoring

Presented in: SPIE BIOS 2021 Authors: Visa Kaivosoja, Zoe Ylöniemi, Juha Lemmetti, Timo Tanila, Lasse Orsila, Petteri Uusimaa, Modulight, Inc. (Finland)    Presented in: SPIE BIOS 2021 Authors: Visa Kaivosoja, Zoe Ylöniemi, Juha Lemmetti, Timo Tanila, Lasse Orsila, Petteri Uusimaa, Modulight, Inc. (Finland) Traditionally one of the biggest challenges with light-based treatment modalities such as photodynamic therapy or different tumor ablation techniques is to determine how much light should be applied to the tissue and how that will be distributed to activate a bio-photonic process or a drug. Different tools have been developed to model light distribution in tissue, but this has not solved the problem of Continue reading →